Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis - Scorecard - MDSpire

Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

  • By

  • Máté Orgoványi

  • Anett Rancz

  • Anca Dolhascu

  • Gergely Agócs

  • Boglárka Lilla Szentes

  • Emese Sipter

  • Péter Hegyi

  • Gábor László Kovács

  • July 2, 2026

  • 0 min

Share

Clinical Scorecard: Identifying Risk Factors Linked to Aggressive Tumor Characteristics in Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis

At a Glance

CategoryDetail
ConditionPapillary Thyroid Microcarcinoma (PTMC)
Key MechanismsRisk factors for aggressive phenotypes include male sex, age, tumor size, multifocality, bilaterality, and BRAFV600E mutation.
Target PopulationPatients with histologically confirmed PTMC
Care SettingSurgical cohorts evaluating post-operative histopathology

Key Highlights

  • Increased odds of central lymph node metastasis associated with male sex and younger age.
  • Tumor size greater than 5 mm significantly linked to extrathyroidal extension.
  • BRAFV600E mutation correlates with aggressive PTMC phenotypes.

Guideline-Based Recommendations

Diagnosis

  • Evaluate individual tumor biology rather than relying solely on diameter-based assessments.

Management

  • Consider risk factors such as age, sex, and genetic mutations when planning treatment.

Monitoring & Follow-up

  • Regular follow-up for patients with identified risk factors for aggressive PTMC.

Risks

  • Higher likelihood of lymph node metastasis and extrathyroidal extension in patients with specific risk factors.

Patient & Prescribing Data

Patients with papillary thyroid microcarcinoma

Management strategies should be tailored based on the presence of aggressive tumor characteristics.

Clinical Best Practices

  • Utilize a multi-parametric approach for risk stratification in PTMC.
  • Incorporate genetic testing for BRAFV600E mutation in risk assessment.

Related Resources & Content

Original Source(s)

Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

  • by Máté Orgoványi, Anett Rancz, Anca Dolhascu, Gergely Agócs, Boglárka Lilla Szentes, Emese Sipter, Péter Hegyi, Gábor László Kovács

  • July 2, 2026

Related Content

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

  • July 1, 2026

  • 1 min
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Correction: GNPAT promotes immunosuppression in hepatocellular carcinoma by activating the plasmalogen-PPARg pathway to drive M2 macrophage polarization